2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease

Jessica Davidson, Elizabeth Molitor, Samantha Moores, Sarah E. Gale, Kanagaraj Subramanian, Xuntian Jiang, Rohini Sidhu, Pamela Kell, Jesse Zhang, Hideji Fujiwara, Cristin Davidson, Paul Helquist, Bruce J. Melancon, Michael Grigalunas, Gang Liu, Farbod Salahi, Olaf Wiest, Xin Xu, Forbes D. Porter, Nina H. PipaliaDana L. Cruz, Edward B. Holson, Jean E. Schaffer, Steven U. Walkley, Frederick R. Maxfield, Daniel S. Ory

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Niemann-Pick type C1 (NPC1) disease is a fatal neurovisceral disease for which there are no FDA approved treatments, though cyclodextrin (HPβCD) slows disease progression in preclinical models and in an early phase clinical trial. Our goal was to evaluate the mechanism of action of a previously described combination-therapy, Triple Combination Formulation (TCF) – comprised of the histone deacetylase inhibitor (HDACi) vorinostat/HPβCD/PEG – shown to prolong survival in Npc1 mice. In these studies, TCF's benefit was attributed to enhanced vorinostat pharmacokinetics (PK). Here, we show that TCF reduced lipid storage, extended lifespan, and preserved neurological function in Npc1 mice. Unexpectedly, substitution of an inactive analog for vorinostat in TCF revealed similar efficacy. We demonstrate that the efficacy of TCF was attributable to enhanced HPβCD PK and independent of NPC1 protein expression. We conclude that although HDACi effectively reduce cholesterol storage in NPC1-deficient cells, HDACi are ineffective in vivo in Npc1 mice.

Fingerprint

Niemann-Pick Diseases
Histone Deacetylase Inhibitors
Cyclodextrins
Pharmacokinetics
Type C Niemann-Pick Disease
Disease Progression
Cholesterol
Clinical Trials
Lipids
vorinostat
Proteins
Therapeutics

Keywords

  • Cholesterol
  • Cyclodextrin
  • Histone deacetylase inhibitors
  • Neurodegeneration
  • Niemann-Pick C
  • NPC1 protein

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease. / Davidson, Jessica; Molitor, Elizabeth; Moores, Samantha; Gale, Sarah E.; Subramanian, Kanagaraj; Jiang, Xuntian; Sidhu, Rohini; Kell, Pamela; Zhang, Jesse; Fujiwara, Hideji; Davidson, Cristin; Helquist, Paul; Melancon, Bruce J.; Grigalunas, Michael; Liu, Gang; Salahi, Farbod; Wiest, Olaf; Xu, Xin; Porter, Forbes D.; Pipalia, Nina H.; Cruz, Dana L.; Holson, Edward B.; Schaffer, Jean E.; Walkley, Steven U.; Maxfield, Frederick R.; Ory, Daniel S.

In: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 01.01.2019.

Research output: Contribution to journalArticle

Davidson, J, Molitor, E, Moores, S, Gale, SE, Subramanian, K, Jiang, X, Sidhu, R, Kell, P, Zhang, J, Fujiwara, H, Davidson, C, Helquist, P, Melancon, BJ, Grigalunas, M, Liu, G, Salahi, F, Wiest, O, Xu, X, Porter, FD, Pipalia, NH, Cruz, DL, Holson, EB, Schaffer, JE, Walkley, SU, Maxfield, FR & Ory, DS 2019, '2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease', Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids. https://doi.org/10.1016/j.bbalip.2019.04.011
Davidson, Jessica ; Molitor, Elizabeth ; Moores, Samantha ; Gale, Sarah E. ; Subramanian, Kanagaraj ; Jiang, Xuntian ; Sidhu, Rohini ; Kell, Pamela ; Zhang, Jesse ; Fujiwara, Hideji ; Davidson, Cristin ; Helquist, Paul ; Melancon, Bruce J. ; Grigalunas, Michael ; Liu, Gang ; Salahi, Farbod ; Wiest, Olaf ; Xu, Xin ; Porter, Forbes D. ; Pipalia, Nina H. ; Cruz, Dana L. ; Holson, Edward B. ; Schaffer, Jean E. ; Walkley, Steven U. ; Maxfield, Frederick R. ; Ory, Daniel S. / 2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease. In: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids. 2019.
@article{98d9cae31cf648d9beaa85c3e210a06f,
title = "2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease",
abstract = "Niemann-Pick type C1 (NPC1) disease is a fatal neurovisceral disease for which there are no FDA approved treatments, though cyclodextrin (HPβCD) slows disease progression in preclinical models and in an early phase clinical trial. Our goal was to evaluate the mechanism of action of a previously described combination-therapy, Triple Combination Formulation (TCF) – comprised of the histone deacetylase inhibitor (HDACi) vorinostat/HPβCD/PEG – shown to prolong survival in Npc1 mice. In these studies, TCF's benefit was attributed to enhanced vorinostat pharmacokinetics (PK). Here, we show that TCF reduced lipid storage, extended lifespan, and preserved neurological function in Npc1 mice. Unexpectedly, substitution of an inactive analog for vorinostat in TCF revealed similar efficacy. We demonstrate that the efficacy of TCF was attributable to enhanced HPβCD PK and independent of NPC1 protein expression. We conclude that although HDACi effectively reduce cholesterol storage in NPC1-deficient cells, HDACi are ineffective in vivo in Npc1 mice.",
keywords = "Cholesterol, Cyclodextrin, Histone deacetylase inhibitors, Neurodegeneration, Niemann-Pick C, NPC1 protein",
author = "Jessica Davidson and Elizabeth Molitor and Samantha Moores and Gale, {Sarah E.} and Kanagaraj Subramanian and Xuntian Jiang and Rohini Sidhu and Pamela Kell and Jesse Zhang and Hideji Fujiwara and Cristin Davidson and Paul Helquist and Melancon, {Bruce J.} and Michael Grigalunas and Gang Liu and Farbod Salahi and Olaf Wiest and Xin Xu and Porter, {Forbes D.} and Pipalia, {Nina H.} and Cruz, {Dana L.} and Holson, {Edward B.} and Schaffer, {Jean E.} and Walkley, {Steven U.} and Maxfield, {Frederick R.} and Ory, {Daniel S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.bbalip.2019.04.011",
language = "English (US)",
journal = "Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids",
issn = "1388-1981",
publisher = "Elsevier",

}

TY - JOUR

T1 - 2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease

AU - Davidson, Jessica

AU - Molitor, Elizabeth

AU - Moores, Samantha

AU - Gale, Sarah E.

AU - Subramanian, Kanagaraj

AU - Jiang, Xuntian

AU - Sidhu, Rohini

AU - Kell, Pamela

AU - Zhang, Jesse

AU - Fujiwara, Hideji

AU - Davidson, Cristin

AU - Helquist, Paul

AU - Melancon, Bruce J.

AU - Grigalunas, Michael

AU - Liu, Gang

AU - Salahi, Farbod

AU - Wiest, Olaf

AU - Xu, Xin

AU - Porter, Forbes D.

AU - Pipalia, Nina H.

AU - Cruz, Dana L.

AU - Holson, Edward B.

AU - Schaffer, Jean E.

AU - Walkley, Steven U.

AU - Maxfield, Frederick R.

AU - Ory, Daniel S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Niemann-Pick type C1 (NPC1) disease is a fatal neurovisceral disease for which there are no FDA approved treatments, though cyclodextrin (HPβCD) slows disease progression in preclinical models and in an early phase clinical trial. Our goal was to evaluate the mechanism of action of a previously described combination-therapy, Triple Combination Formulation (TCF) – comprised of the histone deacetylase inhibitor (HDACi) vorinostat/HPβCD/PEG – shown to prolong survival in Npc1 mice. In these studies, TCF's benefit was attributed to enhanced vorinostat pharmacokinetics (PK). Here, we show that TCF reduced lipid storage, extended lifespan, and preserved neurological function in Npc1 mice. Unexpectedly, substitution of an inactive analog for vorinostat in TCF revealed similar efficacy. We demonstrate that the efficacy of TCF was attributable to enhanced HPβCD PK and independent of NPC1 protein expression. We conclude that although HDACi effectively reduce cholesterol storage in NPC1-deficient cells, HDACi are ineffective in vivo in Npc1 mice.

AB - Niemann-Pick type C1 (NPC1) disease is a fatal neurovisceral disease for which there are no FDA approved treatments, though cyclodextrin (HPβCD) slows disease progression in preclinical models and in an early phase clinical trial. Our goal was to evaluate the mechanism of action of a previously described combination-therapy, Triple Combination Formulation (TCF) – comprised of the histone deacetylase inhibitor (HDACi) vorinostat/HPβCD/PEG – shown to prolong survival in Npc1 mice. In these studies, TCF's benefit was attributed to enhanced vorinostat pharmacokinetics (PK). Here, we show that TCF reduced lipid storage, extended lifespan, and preserved neurological function in Npc1 mice. Unexpectedly, substitution of an inactive analog for vorinostat in TCF revealed similar efficacy. We demonstrate that the efficacy of TCF was attributable to enhanced HPβCD PK and independent of NPC1 protein expression. We conclude that although HDACi effectively reduce cholesterol storage in NPC1-deficient cells, HDACi are ineffective in vivo in Npc1 mice.

KW - Cholesterol

KW - Cyclodextrin

KW - Histone deacetylase inhibitors

KW - Neurodegeneration

KW - Niemann-Pick C

KW - NPC1 protein

UR - http://www.scopus.com/inward/record.url?scp=85066953677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066953677&partnerID=8YFLogxK

U2 - 10.1016/j.bbalip.2019.04.011

DO - 10.1016/j.bbalip.2019.04.011

M3 - Article

C2 - 31051283

AN - SCOPUS:85066953677

JO - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

JF - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

SN - 1388-1981

ER -